4//SEC Filing
Jamil Khurram 4
Accession 0001133416-26-000002
CIK 0001133416other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:07 PM ET
Size
9.0 KB
Accession
0001133416-26-000002
Insider Transaction Report
Form 4
Jamil Khurram
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-31$1.23/sh+8,125$9,994→ 8,125 total - Sale
Common Stock
2025-12-31$4.07/sh−8,125$33,089→ 0 total - Exercise/Conversion
Stock option (right to buy)
2025-12-31−8,125→ 40,625 totalExercise: $1.23From: 2025-12-31Exp: 2035-01-23→ Common Stock (8,500 underlying)
Footnotes (3)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
- [F2]The shares were sold in multiple transactions at prices ranging from $4.00 to $4.15. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0002032345
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 4:07 PM ET
- Size
- 9.0 KB